TuHURA Biosciences Inc (HURA)vsModerna Inc (MRNA)
HURA
TuHURA Biosciences Inc
$2.05
+0.99%
HEALTHCARE · Cap: $133.19M
MRNA
Moderna Inc
$143.97
+5.38%
HEALTHCARE · Cap: $56.02B
Smart Verdict
WallStSmart Research — data-driven comparison
HURA leads profitability with a 0.0% profit margin vs -141.4%. MRNA earns a higher WallStSmart Score of 21/100 (F).
HURA
Avoid16
out of 100
Grade: F
MRNA
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for HURA.
Margin of Safety
+70.0%
Fair Value
$134.97
Current Price
$143.97
$9.00 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Large-cap with strong market position
Conservative balance sheet, low leverage
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Trading at 8.5x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : HURA
The strongest argument for HURA centers on Debt/Equity.
Bull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bear Case : HURA
The primary concerns for HURA are Revenue Growth, EPS Growth, Market Cap.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
HURA profiles as a value stock while MRNA is a turnaround play — different risk/reward profiles.
MRNA is growing revenue faster at 2.1% — sustainability is the question.
HURA generates stronger free cash flow (-9M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
MRNA scores higher overall (21/100 vs 16/100). Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
TuHURA Biosciences Inc
HEALTHCARE · BIOTECHNOLOGY · USA
TuHURA Biosciences Inc is a pioneering biotechnology firm committed to advancing immunotherapy solutions for cancer and autoimmune diseases. The company is actively developing a robust research pipeline focused on significant unmet medical needs, leveraging the human immune system's potential to improve patient outcomes. With strategic partnerships and innovative technologies as its foundation, TuHURA is well-positioned to capitalize on growth opportunities and drive value creation within the evolving biopharmaceutical sector, aspiring to become a key player in the future of healthcare.
Visit Website →Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?